Media stories about Amgen (NASDAQ:AMGN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amgen earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.8907911713888 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Egan Bernal Becomes First Colombian Amgen Tour of California Champion; Countryman Fernando Gaviria Sweeps Sprint Stages at Sacramento Race Conclusion (markets.financialcontent.com)
- Mexican National Team Joins Amgen Tour Of California (capradio.org)
- Amgen Women’s Tour: Stage 2 highlights – Video (cyclingnews.com)
- Amgen brings crowds, color to Placerville (mtdemocrat.com)
- New migraine drug is affordably priced at only $6900 a year (kxlf.com)
Several equities research analysts have commented on AMGN shares. Royal Bank of Canada reaffirmed a “hold” rating and issued a $189.00 price target on shares of Amgen in a report on Wednesday, January 24th. Barclays lowered their target price on shares of Amgen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 5th. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. BidaskClub lowered shares of Amgen from a “hold” rating to a “sell” rating in a research note on Saturday, March 24th. Finally, Mizuho set a $200.00 target price on shares of Amgen and gave the stock a “buy” rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the company’s stock. Amgen has an average rating of “Hold” and an average target price of $191.70.
Shares of Amgen traded up $1.65, hitting $176.30, during mid-day trading on Friday, according to MarketBeat Ratings. 3,377,156 shares of the company were exchanged, compared to its average volume of 3,554,066. Amgen has a 1-year low of $152.16 and a 1-year high of $201.23. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 2.14. The company has a market cap of $115.57 billion, a PE ratio of 14.01, a price-to-earnings-growth ratio of 2.12 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.23. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter in the prior year, the firm earned $3.15 EPS. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. sell-side analysts expect that Amgen will post 13.71 earnings per share for the current year.
Amgen declared that its board has authorized a stock repurchase program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be given a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 annualized dividend and a dividend yield of 2.99%. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $174.10, for a total transaction of $265,502.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 4,575 shares of company stock valued at $818,208. Insiders own 0.19% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.